MNKD

MannKind Corporation NASDAQ

Healthcare ·Biotechnology ·US · mannkindcorp.com

$2.86

Pre-mkt $3.33 +16.29%

Mkt Cap $883.2M

52w Low $2.23 14.7% of range 52w High $6.51

50d MA $2.82 200d MA $4.61

P/E (TTM) 142.0x

EV/EBITDA 77.4x

P/B —

Debt/Equity -9.3x

ROE -11.5%

P/FCF 126.6x

RSI (14) —

ATR (14) —

Beta 1.04

50d MA $2.82

200d MA $4.61

Avg Volume 5.7M

About

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the tre…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 26, 2026	AMC	-0.01	-0.05	-400.0%	3.24	-2.8%	+1.2%	-6.2%	-9.6%	-9.0%	-12.7%	—
Nov 5, 2025	AMC	0.01	0.03	+200.0%	6.06	+1.2%	-5.9%	-7.1%	-10.6%	-13.4%	-13.4%	—
Aug 6, 2025	AMC	0.04	0.00	-94.8%	3.47	+2.9%	-1.2%	+1.4%	-1.4%	+5.5%	+7.5%	—
May 8, 2025	AMC	0.03	0.04	+33.3%	4.63	+0.2%	-1.5%	+3.9%	+1.9%	-1.3%	-1.5%	—
Feb 26, 2025	AMC	0.03	0.03	+0.0%	5.47	+0.0%	-4.4%	-2.4%	-6.2%	-5.9%	-5.9%	—
Nov 7, 2024	AMC	0.06	0.04	-33.3%	7.39	-5.4%	-0.5%	-2.3%	-4.2%	-5.8%	-5.0%	—
Aug 7, 2024	AMC	-0.03	0.05	+250.1%	5.01	+2.0%	+3.6%	+0.8%	+3.6%	+1.2%	+3.6%	—
May 8, 2024	AMC	0.03	0.04	+53.8%	4.40	+3.4%	-2.0%	-1.8%	+0.2%	+2.3%	+1.1%	—
Feb 27, 2024	AMC	—	0.02	—	3.78	+3.2%	+3.7%	+8.7%	+19.0%	+23.0%	+25.7%	—
Nov 7, 2023	AMC	0.01	0.02	+160.4%	3.80	+5.8%	-3.9%	-8.7%	-9.7%	-6.8%	-2.1%	—
Aug 7, 2023	AMC	-0.01	-0.02	-47.2%	4.60	+8.7%	+18.5%	+16.1%	+15.0%	+14.1%	+14.6%	—
May 9, 2023	AMC	-0.05	-0.04	+20.0%	3.80	+5.8%	+15.8%	+11.6%	+11.3%	+19.2%	+15.5%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 28	Wells Fargo	Maintains	Overweight → Overweight	—	$2.63	$2.67	+1.5%	+6.1%	+4.6%	+7.6%	+8.0%	—
Apr 13	Mizuho	Maintains	Outperform → Outperform	—	$2.57	$2.57	+0.0%	+2.7%	+6.6%	+7.8%	+7.0%	+10.5%
Mar 5	Wedbush	Maintains	Outperform → Outperform	—	$2.95	$2.94	-0.3%	-4.1%	-11.5%	-9.2%	-11.5%	-4.4%
Feb 27	Wells Fargo	Maintains	Overweight → Overweight	—	$3.24	$3.15	-2.8%	+1.2%	-6.2%	-9.6%	-9.0%	-12.7%
Feb 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.24	$3.15	-2.8%	+1.2%	-6.2%	-9.6%	-9.0%	-12.7%
Feb 27	RBC Capital	Downgrade	Outperform → Sector Perform	—	$3.24	$3.15	-2.8%	+1.2%	-6.2%	-9.6%	-9.0%	-12.7%
Feb 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.54	$5.54	+0.0%	-36.8%	-41.5%	-40.8%	-45.1%	-47.1%
Jan 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.46	$5.47	+0.2%	+2.2%	+2.4%	+3.3%	+6.0%	+5.9%
Nov 11	Wells Fargo	Maintains	Overweight → Overweight	—	$5.42	$5.34	-1.5%	-3.1%	-3.1%	-6.5%	-6.6%	-8.1%
Nov 11	RBC Capital	Maintains	Outperform → Outperform	—	$5.42	$5.34	-1.5%	-3.1%	-3.1%	-6.5%	-6.6%	-8.1%
Oct 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.88	$4.92	+0.8%	+4.5%	+4.5%	+7.2%	+9.6%	+12.1%
Sep 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.39	$5.40	+0.2%	+4.1%	+0.7%	+3.3%	-0.7%	-1.1%
Sep 5	Oppenheimer	Maintains	Outperform → Outperform	—	$5.34	$5.48	+2.6%	+3.7%	+4.3%	+3.2%	+4.3%	+1.5%
Sep 3	Wells Fargo	Maintains	Overweight → Overweight	—	$5.74	$5.74	+0.0%	-4.0%	-7.0%	-3.5%	-3.0%	-4.0%
Sep 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.59	$6.06	+32.0%	+25.1%	+20.0%	+16.3%	+20.7%	+21.4%
Aug 26	RBC Capital	Maintains	Outperform → Outperform	—	$3.90	$4.12	+5.6%	+4.4%	+15.9%	+15.1%	+17.7%	+47.2%
Aug 7	RBC Capital	Maintains	Outperform → Outperform	—	$3.47	$3.57	+2.9%	-1.2%	+1.4%	-1.4%	+5.5%	+7.5%
Jul 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.08	$4.10	+0.5%	-0.5%	-2.9%	-6.4%	-5.1%	-7.4%
Jul 23	RBC Capital	Maintains	Outperform → Outperform	—	$3.93	$3.93	+0.0%	+4.3%	+3.8%	+3.3%	+0.8%	-2.8%
Dec 19	RBC Capital	Upgrade	Sector Perform → Outperform	—	$5.94	$6.30	+6.1%	+6.1%	+15.3%	+18.2%	+13.5%	+16.0%
Aug 28	Oppenheimer	Maintains	Outperform → Outperform	—	$5.38	$5.46	+1.5%	+9.7%	+17.7%	+16.4%	+13.0%	+13.2%
May 9	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$4.40	$4.55	+3.4%	-2.0%	-1.8%	+0.2%	+2.3%	+1.1%
Mar 15	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$4.50	$4.46	-0.9%	-0.7%	+2.7%	+3.8%	+7.1%	+5.8%
Feb 28	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$3.78	$3.90	+3.2%	+3.7%	+8.7%	+19.0%	+23.0%	+25.7%
Jan 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.70	$3.74	+1.1%	+3.2%	-1.6%	+0.3%	-3.5%	-3.0%
Aug 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.25	$5.29	+0.8%	+0.4%	-0.2%	-3.8%	-5.7%	-5.1%
Aug 8	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$4.60	$5.00	+8.7%	+18.5%	+16.1%	+15.0%	+14.1%	+14.6%
May 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.40	$4.42	+0.5%	-3.6%	-3.9%	+3.0%	-0.2%	+3.4%
Feb 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.41	$5.55	+2.6%	-0.6%	-2.4%	-10.7%	-11.1%	-10.0%
Nov 9	SVB Leerink	Maintains	Outperform → Outperform	—	$3.81	$3.82	+0.3%	+1.3%	+11.5%	+15.0%	+11.8%	+15.2%
Feb 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.72	$2.65	-2.6%	-3.7%	+1.1%	+19.1%	+15.1%	+10.3%
Mar 5	SVB Leerink	Maintains	Outperform → Outperform	—	$3.38	$3.49	+3.3%	+8.6%	+7.4%	+12.4%	+13.9%	+16.9%
Mar 1	Maxim Group	Downgrade	Hold → Sell	—	$2.93	$2.84	-3.1%	-3.1%	-3.4%	-3.1%	-4.1%	-5.5%
Nov 1	Maxim Group	Downgrade	Buy → Hold	—	$3.29	$3.28	-0.3%	-8.5%	-1.8%	-0.9%	-1.8%	-1.2%
Nov 16	Griffin Securities	Downgrade	Buy → Neutral	—	$12.20	$11.45	-6.1%	-7.4%	-7.4%	-4.5%	-1.2%	+1.2%
Nov 4	RBC Capital	Downgrade	Outperform → Underperform	—	$16.15	$15.25	-5.6%	-7.4%	-13.6%	-11.1%	-18.6%	-28.8%
Sep 9	Piper Sandler	Downgrade	Neutral → Underweight	—	$20.35	$18.60	-8.6%	-10.1%	-7.9%	-9.1%	-12.3%	-11.5%
Sep 9	PiperJaffray	Downgrade	Neutral → Underweight	—	$20.35	$18.60	-8.6%	-10.1%	-7.9%	-9.1%	-12.3%	-11.5%
May 11	JP Morgan	Downgrade	Neutral → Underweight	—	$19.05	$18.25	-4.2%	-4.7%	-4.2%	-4.7%	-4.7%	+4.9%
Mar 3	Goldman Sachs	Downgrade	Neutral → Sell	—	$33.20	$30.60	-7.8%	-7.2%	-10.5%	-13.7%	-17.6%	-19.6%
Jul 1	MLV & Co.	Downgrade	Buy → Hold	—	$54.80	$54.00	-1.5%	-5.8%	-9.9%	-8.8%	-9.6%	-11.6%
May 14	PiperJaffray	Upgrade	Underweight → Neutral	—	$32.90	$33.30	+1.2%	+6.5%	+5.3%	+6.7%	+12.3%	+15.0%
May 14	Piper Sandler	Upgrade	Underweight → Neutral	—	$32.90	$33.30	+1.2%	+6.5%	+5.3%	+6.7%	+12.3%	+15.0%
Apr 2	McNicoll Lewis Vlak	Maintains	Buy → Buy	—	$21.00	$38.75	+84.5%	+66.4%	+65.0%	+63.6%	+50.5%	+55.7%
Mar 31	Piper Sandler	Downgrade	Neutral → Underweight	—	$24.15	$22.20	-8.1%	-16.8%	-13.0%	+44.7%	+43.5%	+42.2%
Mar 31	PiperJaffray	Downgrade	Neutral → Underweight	—	$24.15	$22.20	-8.1%	-16.8%	-13.0%	+44.7%	+43.5%	+42.2%
Sep 6	Bank of America	Downgrade	Neutral → Underperform	—	$31.50	$30.00	-4.8%	-7.0%	-5.1%	-4.0%	-6.7%	-7.0%
Sep 6	BofA Securities	Downgrade	Neutral → Underperform	—	$31.50	$30.00	-4.8%	-7.0%	-5.1%	-4.0%	-6.7%	-7.0%
Jun 7	Bank of America	Downgrade	Buy → Neutral	—	$38.25	$37.30	-2.5%	-2.5%	-2.0%	+0.0%	-0.1%	-2.4%
Jun 7	BofA Securities	Downgrade	Buy → Neutral	—	$38.25	$37.30	-2.5%	-2.5%	-2.0%	+0.0%	-0.1%	-2.4%

Recent Filings

8-K

Mannkind Corporation -- 8-K Filing

MannKind's Furoscix ReadyFlow Autoinjector will receive FDA review completion by July 26, 2026, potentially expanding its commercial portfolio and supporting future revenue growth if approved.

Feb 26

Data updated apr 26, 2026 12:47pm · Source: massive.com